Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million
Sino Biopharmaceutical (HKG: 1177) announced that its subsidiary, Chia Tai Tianqing (CTTQ), entered into an...
Cipla
Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements
Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals,...
Eli Lilly Partners with Cipla to Distribute New Tirzepatide Brand “Yurpeak” in India
Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited (BOM: 500087, NSE: CIPLA) today announced a...
CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...
Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...
Bio-Thera Secures FDA Approval for Avzivi, a Biosimilar to Roche’s Avastin
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received market approval from the...